Shopping Cart

No products in the cart.

Custom Custom Cart0

Programme

Join us for our Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders from June 17th to 19th, 2023. Explore multidisciplinary perspectives on these crucial health issues with world-renowned experts. Our comprehensive three-day program covers everything from basic science lectures to clinical trials, focusing on new research and advancements in the field. Register now and help redefine the field to create lasting impacts on patients worldwide

CET time zone

Day 1: 17 June 2023

Exploring Sarcopenia and Cachexia: Multidisciplinary Perspectives

Welcome to the first day of our Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders. Discover world-renowned experts to discuss the latest research and advancements in the field. 

Opening Session

12:30 - 13:45

A - Opening Session

Chairs: Stefan Anker, Vickie Baracos and Gianluigi Savarese

Welcome
Stefan Anker

“Prometheus” basic science key note lecture:
Central mechanisms in cachexia: bench to bedside
Daniel Marks

 “Hippocrates” clinical science key note lecture:
Small non-coding RNA profiling and cachexia in patients with cancer

Maurizio Muscaritoli

JCSM & SCWD – update 2023
Stephan von Haehling & Stefan Anker

Chairs & Speakers

Stefan Anker, Germany

Vickie Baracos, Germany

Gianluigi Savarese, Sweden
Daniel Marks, MD, PhD
Daniel Marks, USA
Maurizio Muscaritoli, Italy
Maurizio Muscaritoli, Italy
Stephan von Haehling, Germany

Lunch Session 1

14:00-15:00

Sarcopenia as a multisystem disorder

Chair: Ivan Aprahamian

Sarcopenia and diabetes
Gustavo Duque

Sarcopenia and stroke/dysphagia
Hidetaka Wakabayashi

Sarcopenia and heart failure
Gianluigi Savarese

Chairs & Speakers

Ivan Aprahamian, Brazil
Ivan Aprahamian, Brazil
Gustavo Duque, Canada
Hidetaka Wakabayashi, Japan
Gianluigi Savarese, Sweden

General Sarcopenia

15:00 - 16:15

B - The fat story of sarcopenia – the fat in muscle

Chair: Ivan Aprahamian & Marianne Hjermstad

Intermuscular fat infiltration in sarcopenia
Gustavo Duque

Clinical implications of fat infiltration in sarcopenia 
Reshma Merchant

Metabolic role of fat in muscle
James Carson

Targeting ACTIVIN receptors and the effect on muscle and fat tissue
David Glass

Chairs & Speakers

Ivan Aprahamian, Brazil
Ivan Aprahamian, Brazil
Marianne Hjermstad, Norway
Marianne Hjermstad, Norway
Gustavo Duque, Canada 
Reshma Merchant, Singapore
James Carson, USA
David Glass, USA

General Cachexia

15:00 - 16:15

C - Novel cancer cachexia biomarkers

Chairs: Nick Hoogenraad & Stephan von Haehling

The MIC-1/GDF15 story – biomarker and therapeutic target
Samuel Breit

Targeted therapy relapse models to study cachexia development in lung cancer
Swarnali Acharya

Tumor genetic mutations and cancer cachexia – clinical findings
Puneeth Iyengar

A geroscience approach to frailty biomarker discovery in cancer patients
Emanuele Marzetti

Chairs & Speakers

Nick Hoogenraad, Australia
Nick Hoogenraad, Australia
Stephan von Haehling, Germany
Samuel Breit, Australia
Swarnali Acharya, USA
Puneeth Iyengar, USA 
Emanuele Marzetti, Italy

Coffee Break

16:15 - 17:15

Coffee Break

Posters

16:20-17:10

Poster Session 1

Rapid Fire Abstracts Session 1

General Sarcopenia

17:15-18:30

D - Sarcopenia in lung disease: interplay with chronic conditions

Chair: Abigail Mackey & Hidetaka Wakabayashi

Definition, diagnostic criteria and treatment of respiratory sarcopenia
Akira Tamaki

Cytokine signaling in adipose tissue browning and muscle wasting in CKD
Robert Mak

COPD and other chronic diseases
Marielle Engelen

Sarcopenia in cardio-respiratory illnesses
Stephan von Haehling

Chairs & Speakers

Abigail Mackey, Denmark
Abigail Mackey, Denmark
Hidetaka Wakabayashi, Japan
Akira Tamaki, Japan 
Robert Mak, USA
Marielle Engelen, USA
Stephan von Haehling, Germany

General Cachexia

17:15-18:30

E - Liver metabolism in cancer and cachexia

Chairs: Maria Rohm & Jochen Springer

Cancer-induced rewiring of metabolism and zonation in the liver
Shinpei Kawaoka

Targeting bile acid metabolism to counteract cancer cachexia
Laure Bindels

Liver mitochondrial function in cancer cachexia
Marilia Seelaender

Liver NAD+ metabolism in cancer- and chemotherapy-induced cachexia
Fabio Penna

Chairs & Speakers

Maria Rohm, PhD
Maria Rohm, Germany
Jochen Springer, Germany
Shinpei Kawaoka, Japan
Laure Bindels, Belgium
Marilia Seelaender, Brazil
Fabio Penna, Italy

Register Now!

Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.

Day 2: 18 June 2023

Comprehensive Exploration of Cancer Cachexia and Aging-Related Sarcopenia

Doscover the second day of our programme, dedicated to exploring the complexities of cancer cachexia and aging-related sarcopenia. With a stellar lineup of international experts presenting their latest research and engaging in insightful panel discussions

café

08:00-08:50

Ken Fearon Career Café

Nutrition

09:00-10:15

F - Nutritional issues in cachexia

Chairs: Florian Strasser & Joanne Reid

Appetite, food quantity and quality in cancer cachexia
Alessio Molfino

Gut barrier, nutrient absorption and cachexia
Laure Bindels

Exercise, nutrition and omega-3 PUFA Interventions for kidney cachexia
Adrian Slee

Examining biological sex variability in cancer-induced cachexia
Nicholas P. Greene

Chairs & Speakers

Florian Strasser, Switzerland
Joanne Reid, UK
Alessio Molfino
Alessio Molfino, Italy 
Laure Bindels, Belgium
Adrian Slee
Adrian Slee, UK
Nicholas P. Greene, USA

Mechanisms, Diagnostics (Basic / Translational)

09:00-10:15

G - New mechanisms of cancer cachexia

Chairs: Andrea Bonetto & Paola Costelli

Tissue crosstalk during cancer cachexia: consequences of altered metabolic networks
Selma Masri

Inflammation as target in cancer cachexia
Erin E Talbert

Examining the relationship between mitochondrial function and muscle force in cancer cachexia
Luca Delfinis

Deletion of FNDC5/Irisin protects against cancer induced cachexia syndrome
Fabrizio Pin

Chairs & Speakers

Andrea Bonetto Ph.D.
Andrea Bonetto, USA
Paola Costelli, Italy
Selma Masri Ph.D.
Selma Masri, USA
Erin E Talbert, USA
Luca Delfinis, Canada
Fabrizio Pin, USA
Fabrizio Pin, USA

Coffee Break

10:15-11:15

Coffee Break

Posters

10:20-11:10

Poster Session 2

Rapid Fire Abstracts Session 2

GENERAL SARCOPENIA

11:15-12:30

H - Update on aging and immobilisation related sarcopenia

Chair: Philip Atherton, UK & Robert Mankowski

Effects of aging on human muscle atrophy with immobilization
Stuart Phillips

The human neuromuscular junction in ageing and exercise
Abigail Mackey

The role of nutrition in aging: appetite loss
Ivan Aprahamian

Brain muscle cross talk
Reshma Merchant

Chairs & Speakers

Philip Atherton, UK
Robert Mankowski, USA

Robert Mankowski, USA

Stuart Phillips, Canada
Stuart Phillips, Canada
Abigail Mackey, Denmark
Abigail Mackey, Denmark
Ivan Aprahamian, Brazil
Ivan Aprahamian, Brazil
Reshma Merchant, Singapore

GENERAL CACHEXIA

11:15-12:30

I - The role of extracellular vesicles in wasting

Chairs: Samuel Breit & Adrian Slee

Tumour-derived exosomes
Joanna Lima

Intracellular peptides: potential biomarkers and therapeutic targets
Patrícia Reckziegel

Extracellular vesicles and inflammation: from cachexia to COVID-19
Marilia Seelaender

Tumor-host cross-talk: focus on the extracellular vesicles
Paola Costelli

Chairs & Speakers

Samuel Breit, Australia
Adrian Slee
Adrian Slee, UK
Joanna Lima, UK
Joanna Lima, UK
Patrícia Reckziegel, Brazil
Patrícia Reckziegel, Brazil
Marilia Seelaender, Brazil
Paola Costelli, Italy

Lunch Break

12:30-13:30

Lunch Break

Cancer Cachexia Therapeutics

13:30-14:45

J - Endpoints in cancer cachexia clinical trials

Panel: Jeffrey Crawford, Jose Garcia, Frank Misselwitz, Maurizio Muscaritoli, Richard Skipworth

Physical function endpoints
Barry Laird

Appetite and dietary intake endpoints in cancer cachexia trials
Tora Solheim

Quality of life endpoints
Marianne Hjermstad

Approvable endpoints for cancer cachexia – an evolving field
Stefan Anker

Panel & Speakers

Jeffrey Crawford, USA
Jose Garcia, USA
Frank Misselwitz, Germany
Maurizio Muscaritoli, Italy

Maurizio Muscaritoli, Italy

Richard Skipworth, UK
Barry Laird - Senior Clinical Lecturer in Palliative Medicine
Barry Laird, UK
Tora Solheim, Norway
Tora Solheim, Norway
Marianne Hjermstad, Norway
Marianne Hjermstad, Norway

Stefan Anker, Germany

Cancer Cachexia Therapeutics

13:30-14:45

K - New cachexia treatment approaches on the horizon

Chairs: Mauricio Berriel Diaz & Nicolaas Deutz

Anti-Fn14 therapy for cancer cachexia
Nick Hoogenraad

Peptide-based therapeutic approaches in cancer cachexia
Stephan Herzig

Targeting the TGFbeta pathway
Marcus D. Goncalves

Modulating metabolic pathways – impact on cachexia and malnutrition
Bei B. Zhang

Chairs & Speakers

Mauricio Berriel Diaz, Germany
Nicolaas Deutz, USA

Nicolaas Deutz, USA

Nick Hoogenraad, Australia
Nick Hoogenraad, Australia
Stephan Herzig, Germany
Stephan Herzig, Germany
Marcus D. Goncalves, USA
Marcus D. Goncalves, USA
Bei B. Zhang, Ph.D.
Bei B. Zhang, USA

Coffee Break

14:45-15:45

Coffee Break

Posters

14:50-15:40

Poster Session 3

Rapid Fire Abstracts Session 3

Cancer Cachexia Therapeutics

15:45-17:00

L - Emerging trials in cancer cachexia

Chairs & Panelists:  Stefan Anker, Maurizio Muscaritoli

Update on ponsegromab early clinical trial
Jeffrey Crawford

Multimodal intervention for cancer cachexia – MENAC study
Barry Laird

Pilot study of macimorelin for cancer cachexia
Jose Garcia

Chairs, Panel & Speakers

Stefan Anker, Germany

Maurizio Muscaritoli, Italy

Maurizio Muscaritoli, Italy

Jeffrey Crawford, USA
Barry Laird - Senior Clinical Lecturer in Palliative Medicine
Barry Laird, UK
Jose Garcia, USA

Mechanisms, Diagnostics (Basic / Translational)

15:45-17:00

M - Tissue crosstalk in cancer cachexia

Chair: Stephan Herzig & Fabrizio Pin

Adipocytokines in patients with cancer cachexia
Richard Skipworth

Crosstalk of lipid metabolism and inflammation drives cachexia
Maria Rohm

Liver-derived factors contributing to cancer cachexia
Mauricio Berriel Diaz

Mechanisms of bioamplification in cancer cachexia
Daniel Marks

Chairs & Speakers

Stephan Herzig, Germany
Stephan Herzig, Germany
Fabrizio Pin, USA
Fabrizio Pin, USA
Richard Skipworth, UK
Maria Rohm, PhD
Maria Rohm, Germany
Mauricio Berriel Diaz, Germany
Daniel Marks, MD, PhD
Daniel Marks, USA

Break

17:00-17:15

Break

Late Breaking Trials Session

17:15-18:30

N - Emerging trails and late breaking results in cancer cachexia

Mechanisms, Diagnostics (Basic / Translational)

17:15-18:30

O - New insights into the mechanisms of cancer-associated muscle wasting

Chair: James Carson & Julien Gondin

Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of activin
Teresa Zimmers

FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness
Andrew Judge

Liver metastases enhance the pro-cachectic signaling in colorectal cancer hosts
Andrea Bonetto

Cancer preferentially causes fast muscle mass loss through UBR2-mediated ubiquitylation of myosin heavy chain IIb and IIx
Yi-Ping Li

Chairs & Speakers

James Carson, USA
Julien Gondin, France

Julien Gondin, France

Teresa Zimmers, USA
Teresa Zimmers, USA
Andrew Judge, PhD
Andrew Judge, USA
Andrea Bonetto Ph.D.
Andrea Bonetto, USA
Yi-Ping Li, USA

Register Now!

Embrace this opportunity to redefine the field and create lasting impact in the lives of patients worldwide.

Day 3: 19 June 2023

Exploring the Intricacies of Muscle Wasting and Microbiome in Cancer Cachexia

Day three of our programme plunges us into the intricacies of muscle wasting and the microbiome’s influence in cancer cachexia. We are pleased to present a distinguished gathering of international experts, eager to share their groundbreaking research and partake in dynamic discussions.

Award Session

8:00-8:50

P - Young Investigators Award Session

Mechanisms, Diagnostics (Basic / Translational)

9:00-10:15

Q - CURRENT LIMITATIONS IN PRESERVING MUSCLE IN CANCER

Chairs: Andrea Bonetto, USA, Erin Talbert, USA

Pathological remodeling of respiratory muscles during cancer: mechanisms and therapeutic targets
Sarah Judge, USA

Molecular basis and clinical relevance of insulin resistance in cancer cachexia
Lykke Sylow, Denmark

Neuromuscular electrical stimulation limits muscle weakness and wasting and modulates satellite cell function and niche during cancer cachexia
Julien Gondin, France

Chemotherapy-specific effects on cardiorespiratory status and body composition
Ashley Smuder, USA

Chairs & Speakers

Andrea Bonetto Ph.D.
Andrea Bonetto, USA
Erin E Talbert, USA

Sarah Judge, USA

Lykke Sylow, Denmark

Lykke Sylow, Denmark

Julien Gondin, France

Julien Gondin, France

Ashley Smuder, USA

Coffee Break

10:15-11:15

Coffee Break

Posters

10:20-11:20

Poster Session 4

Nutrition

11:15-12:30

R - New concepts in preventing muscle wasting in critically ill patients

Chairs: Maurizio Muscaritoli & Joanne Reid

Anabolic resistance in critically Ill patients
Olav Rooyackers

Ketogenic feeding in the critically ill patients
Zudin Puthucheary

Persistent inflammation, immunosuppression and catabolism syndrome and the role nutrition in the surgical ICU
Robert Mankowski

The metabolic response to critical illness – a therapeutic target?
Nicolaas Deutz

Speakers

Maurizio Muscaritoli, Italy

Maurizio Muscaritoli, Italy

Joanne Reid, UK
Olav Rooyackers, Sweden

Olav Rooyackers, Sweden

Zudin Puthucheary, UK

Robert Mankowski, USA

Robert Mankowski, USA

Nicolaas Deutz, USA

Nicolaas Deutz, USA

Lunch Break

12:30-13:30

Lunch Break

Cancer Cachexia Therapeutics

13:30-14:45

S - The microbiome and other novel therapeutic targets in cancer cachexia

Chairs: Laure Bindels & Denis Guttridge

Gut microbiota alterations in patients with cancer cachexia
Sander Rensen

Gut microbiota and muscle: from proof-of-concept to molecular mechanisms
Camille Lefevre

Fecal microbiota transplantation (FMT) in cancer cachexia
Laurence Genton

Targeting CXCR2 signaling counteracts cancer cachexia
Andrew Judge

Chairs & Speakers

Laure Bindels, Belgium
Denis Guttridge, USA
Sander Rensen, The Netherlands

Sander Rensen, The Netherlands

Camille Lefevre, Belgium

Camille Lefevre, Belgium

Laurence Genton, Switzerland

Laurence Genton, Switzerland

Andrew Judge, PhD

Andrew Judge, USA

HIGHLIGHTS SESSION

14:45-15:45

T - Highlights Session

Chair: Stephan von Haehling

Basic Science
Jochen Springer

Nutrition
Ivan Aprahamian

Sarcopenia
Vickie Baracos

Cancer Cachexia
Teresa Zimmers

Awards

Chair & Speakers

Stephan von Haehling, Germany
Jochen Springer, Germany
Ivan Aprahamian, Brazil
Ivan Aprahamian, Brazil

Vickie Baracos, Germany

Teresa Zimmers, USA
Teresa Zimmers, USA

Supporting SCWD's Mission to Advance Medical Research

Our Valued Sponsors 2023

JOIN US FOR THE LEADING INTERNATIONAL CONGRESS ON CACHEXIA AND SARCOPENIA

More Than 63 International Speakers

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!

Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. Guided by its core values of quality, respect, and integrity, by its track record of over forty years of commercial execution, and by its commitment to extending and improving the lives of cancer patients globally, Helsinn is the partner of choice for the biotech and pharma sector. With its leading position in cancer supportive care and strong focus in oncology and rare diseases, Helsinn is able to reach patients worldwide through its integrated CMC/manufacturing/supply and commercial platform complemented by scientific and technological expertise.

Helsinn has a commercial presence in 190 countries either directly, with its operating subsidiaries in the U.S. and China, or via its network of over forty long-standing trusted partners who share the same vision and values. The fully integrated supply chain and product development provided through its subsidiary in Ireland, Helsinn Birex Pharmaceuticals Ltd., which cater to specific customer needs, are among the key services Helsinn offers its partners.

The Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Sustainability is at the heart of everything it does, which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn please visit www.helsinn.com and follow us on Twitter and LinkedIn

Days
Hours
Minutes
Seconds

Unlock your potential at the Ken Fearon Career Café – Meet the Mentors event! Don’t miss this unique opportunity for young scientists (up to 35 years) to gain valuable career guidance from top SCWD mentors. Apply by May 21, 2023, and take your career to new heights!